ARHGEF4 predicts poor prognosis and promotes cell invasion by influencing ERK1/2 and GSK-3α/β signaling in pancreatic cancer

Taniuchi,Keisuke; Furihata,Mutsuo; Naganuma,Seiji; Saibara,Toshiji

doi:10.3892/ijo.2018.4549

ARHGEF4 predicts poor prognosis and promotes cell invasion by influencing ERK1/2 and GSK-3α/β signaling in pancreatic cancer

Authors:
- Keisuke Taniuchi
- Mutsuo Furihata
- Seiji Naganuma
- Toshiji Saibara
View Affiliations

Affiliations: Departments of Endoscopic Diagnostics and Therapeutics, Kochi University, Nankoku, Kochi 783-8505, Japan, Departments of Pathology, Kochi University, Nankoku, Kochi 783-8505, Japan
Published online on: August 31, 2018 https://doi.org/10.3892/ijo.2018.4549
Pages: 2224-2240

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rho guanine nucleotide exchange factor 4 (ARHGEF4) is a guanine nucleotide exchange factor that is specific for Rac1 and Cdc42. The aim of the present study was to investigate the role of ARHGEF4 in the motility and invasiveness of pancreatic cancer cells. Evaluation of an immunohistochemical staining of 102 resected pancreatic cancer samples demonstrated that high ARHGEF4 expression was correlated with an independent predictor of worse overall survival in univariate and multivariate analyses. Immunofluorescence analyses and Matrigel invasion assays demonstrated that suppression of ARHGEF4 inhibited the formation of membrane protrusions, and in turn inhibited cell motility and invasion. A phosphoprotein array analysis demonstrated that knockdown of ARHGEF4 decreased phosphorylated extracellular signal-regulated kinase (ERK)1/2 and glycogen synthase kinase-3 (GSK-3)α/β in pancreatic cancer cells, and ERK1/2 and GSK-3α/β were associated with ARHGEF4-related motility and invasiveness through an increase in cell protrusions. These results suggested that ARHGEF4 stimulates ERK1/2 and GSK-3α/β, and provided evidence that ARHGEF4 promotes cell motility and invasiveness. Inhibition of ARHGEF4 may be a novel approach to a targeted molecular therapy, as any such therapy would limit the motility and invasiveness of pancreatic cancer cells.

View Figures

View References

1	Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y, Higuchi O and Akiyama T: Asef, a link between the tumor suppressor APC and G-protein signaling. Science. 289:1194–1197. 2000. View Article : Google Scholar : PubMed/NCBI
2	Thiesen S, Kübart S, Ropers HH and Nothwang HG: Isolation of two novel human RhoGEFs, ARHGEF3 and ARHGEF4, in 3p13-21 and 2q22. Biochem Biophys Res Commun. 273:364–369. 2000. View Article : Google Scholar : PubMed/NCBI
3	Kawasaki Y, Sato R and Akiyama T: Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol. 5:211–215. 2003. View Article : Google Scholar : PubMed/NCBI
4	Akiyama T and Kawasaki Y: Wnt signalling and the actin cytoskeleton. Oncogene. 25:7538–7544. 2006. View Article : Google Scholar : PubMed/NCBI
5	Mitin N, Betts L, Yohe ME, Der CJ, Sondek J and Rossman KL: Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. Nat Struct Mol Biol. 14:814–823. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kawasaki Y, Tsuji S, Sagara M, Echizen K, Shibata Y and Akiyama T: Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase. J Biol Chem. 284:22436–22443. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kawasaki Y, Tsuji S, Muroya K, Furukawa S, Shibata Y, Okuno M, Ohwada S and Akiyama T: The adenomatous polyposis coli-associated exchange factors Asef and Asef2 are required for adenoma formation in Apc(Min/+)mice. EMBO Rep. 10:1355–1362. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kawasaki Y, Jigami T, Furukawa S, Sagara M, Echizen K, Shibata Y, Sato R and Akiyama T: The adenomatous polyposis coli-associated guanine nucleotide exchange factor Asef is involved in angiogenesis. J Biol Chem. 285:1199–1207. 2010. View Article : Google Scholar :
9	DiMagno EP, Reber HA and Tempero MA; American Gastroenterological Association: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 117:1464–1484. 1999. View Article : Google Scholar : PubMed/NCBI
10	Taniuchi K, Furihata M, Hanazaki K, Saito M and Saibara T: IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer. Oncotarget. 5:6832–6845. 2014. View Article : Google Scholar : PubMed/NCBI
11	Taniuchi K, Furihata M and Saibara T: KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells. Neoplasia. 16:1082–1093. 2014. View Article : Google Scholar : PubMed/NCBI
12	Tsuboi M, Taniuchi K, Furihata M, Naganuma S, Kimura M, Watanabe R, Shimizu T, Saito M, Dabanaka K, Hanazaki K, et al: Vav3 is linked to poor prognosis of pancreatic cancers and promotes the motility and invasiveness of pancreatic cancer cells. Pancreatology. 16:905–916. 2016. View Article : Google Scholar : PubMed/NCBI
13	Japan Pancreatic Society: Classification of Pancreatic Carcinoma. 2nd English edition: Kanehara & Co.; Tokyo: 2003
14	Sobin LH, Gospodarowicz MK and Witteknd C: TNM classification of malignant tumors. 7th edition. Wiley-Blackwell; New York, NY: pp. 132–135. 2009
15	Kondo S: Japanese pancreas society staging systems for pancreatic cancer In Pancreatic Cancer. Springer; New York, NY: pp. 1035–1050. 2010
16	Taniuchi K, Furihata M, Naganuma S, Dabanaka K, Hanazaki K and Saibara T: BCL7B, a predictor of poor prognosis of pancreatic cancers, promotes cell motility and invasion by influencing CREB signaling. Am J Cancer Res. 8:387–404. 2018.
17	Iwamura T, Katsuki T and Ide K: Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res. 78:54–62. 1987.PubMed/NCBI
18	Taniuchi K, Nishimori I and Hollingsworth MA: Intracellular CD24 inhibits cell invasion by posttranscriptional regulation of BART through interaction with G3BP. Cancer Res. 71:895–905. 2011. View Article : Google Scholar : PubMed/NCBI
19	Taniuchi K, Furihata M, Naganuma S, Dabanaka K, Hanazaki K and Saibara T: PODXL, linked to poor prognosis of pancreatic cancers, promotes cell invasion via binding to gelsolin. Cancer Sci. 107:1430–1442. 2016. View Article : Google Scholar : PubMed/NCBI
20	Tanouchi A, Taniuchi K, Furihata M, Naganuma S, Dabanaka K, Kimura M, Watanabe R, Kohsaki T, Shimizu T, Saito M, et al: CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells. J Exp Clin Cancer Res. 35:1902016. View Article : Google Scholar : PubMed/NCBI
21	Andea A, Sarkar F and Adsay VN: Clinicopathological correlates of pancreatic intraepithelial neoplasia: A comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol. 16:996–1006. 2003. View Article : Google Scholar : PubMed/NCBI
22	Deer EL, González-Hernández J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA and Mulvihill SJ: Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 39:425–435. 2010. View Article : Google Scholar : PubMed/NCBI
23	Taniuchi K, Furihata M, Iwasaki S, Tanaka K, Shimizu T, Saito M and Saibara T: RUVBL1 directly binds actin filaments and induces formation of cell protrusions to promote pancreatic cancer cell invasion. Int J Oncol. 44:1945–1954. 2014. View Article : Google Scholar : PubMed/NCBI
24	Taniuchi K, Yokotani K and Saibara T: BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1. Neoplasia. 14:440–450. 2012. View Article : Google Scholar : PubMed/NCBI
25	Yip-Schneider MT and Schmidt CM: MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Pancreas. 27:337–344. 2003. View Article : Google Scholar : PubMed/NCBI
26	Liao X, Zhang L, Thrasher JB, Du J and Li B: Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther. 2:1215–1222. 2003.PubMed/NCBI
27	Min KJ, Han MA, Kim S, Park JW and Kwon TK: Osthole enhances TRAIL-mediated apoptosis through downregulation of c-FLIP expression in renal carcinoma Caki cells. Oncol Rep. 37:2348–2354. 2017. View Article : Google Scholar : PubMed/NCBI
28	Ahrendt SA and Pitt HA: Surgical management of pancreatic cancer. Oncology (Williston Park). 16:725–734. 736–738. 7407432002.
29	Rescher U and Gerke V: Annexins - unique membrane binding proteins with diverse functions. J Cell Sci. 117:2631–2639. 2004. View Article : Google Scholar : PubMed/NCBI
30	Itoh RE, Kiyokawa E, Aoki K, Nishioka T, Akiyama T and Matsuda M: Phosphorylation and activation of the Rac1 and Cdc42 GEF Asef in A431 cells stimulated by EGF. J Cell Sci. 121:2635–2642. 2008. View Article : Google Scholar : PubMed/NCBI
31	Farkas A, Szatmári E, Orbók A, Wilhelm I, Wejksza K, Nagyoszi P, Hutamekalin P, Bauer H, Bauer HC, Traweger A, et al: Hyperosmotic mannitol induces Src kinase-dependent phosphorylation of beta-catenin in cerebral endothelial cells. J Neurosci Res. 80:855–861. 2005. View Article : Google Scholar : PubMed/NCBI
32	Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA and Jove R: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA. 98:7319–7324. 2001. View Article : Google Scholar : PubMed/NCBI
33	Levin VA: Basis and importance of Src as a target in cancer. Cancer Treat Res. 119:89–119. 2004. View Article : Google Scholar : PubMed/NCBI
34	He Y, Wang L, Liu W, Zhong J, Bai S, Wang Z, Thomas DG, Lin J, Reddy RM, Ramnath N, et al: MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. Sci Rep. 5:114712015. View Article : Google Scholar : PubMed/NCBI
35	Taniuchi K, Furihata M, Hanazaki K, Iwasaki S, Tanaka K, Shimizu T, Saito M and Saibara T: Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity. Pancreas. 44:331–340. 2015. View Article : Google Scholar :
36	Wilson W III and Baldwin AS: Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/ beta in pancreatic cancer. Cancer Res. 68:8156–8163. 2008. View Article : Google Scholar : PubMed/NCBI
37	Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, Kawakami K and Minamoto T: An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer Agents Med Chem. 9:1114–1122. 2009. View Article : Google Scholar : PubMed/NCBI